Bank of America Q2 profit beats estimates
Bengaluru
BANK of America Corp (BofA) beat estimates for quarterly profit on Wednesday, as the United States' second-largest lender's loan book benefited from a healthy domestic economy.
Consumer banking has held up for the big Wall Street banks that have reported second-quarter results this week, cushioning a blow from weakness in trading and advisory businesses.
But warning signs also emerged with JPMorgan, Citigroup and Well Fargo reporting a dip in margins, stoking fears that interest rate cuts could further pressure profit by reducing the spread between what banks charge on loans and pay on deposits.
BofA, however, bucked the trend and reported a 3 basis-point increase in its interest margin to 2.44 per cent for the second quarter.
The lender is the most sensitive of the big US banks to interest rate changes because of its large deposit stock and rate-sensitive mortgage securities. Total loans in its consumer banking unit rose 6 per cent, while deposits were up 3 per cent, pushing income from the business up 13 per cent to US$3.3 billion.
Net income applicable to common shareholders rose 10 per cent to US$7.11 billion, or 74 US cents per share, in the second quarter ended June 30. Excluding items, the bank earned 75 US cents per share.
Revenue, net of interest expense, was up about 2 per cent at US$23.08 billion. Analysts had expected a profit of 71 US cents per share and revenue of US$23.2 billion, according to IBES data from Refinitiv. REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
UMS Holdings Q1 net profit drops 44% to S$9.8 million
SIA Engineering H2 profit rises 11.5% to S$37.8 million on robust aviation MRO demand
Great Eastern shares jump 39% as OCBC mounts S$1.4 billion privatisation bid at S$25.60 per share
US: Wall St opens higher, focus on comments from Fed officials
Vicom Q1 net profit up 1.3% to S$6.9 million
Sanofi inks US$1.2 billion vaccine licensing deal with Novavax